keyword
https://read.qxmd.com/read/38612725/the-predictive-role-of-serum-lipid-levels-p53-and-ki-67-according-to-molecular-subtypes-in-breast-cancer-a-randomized-clinical-study
#21
JOURNAL ARTICLE
Ionut Flaviu Faur, Amadeus Dobrescu, Ioana Adelina Clim, Paul Pasca, Catalin Prodan-Barbulescu, Cristi Tarta, Andreea-Adriana Neamtu, Dan Brebu, Carmen Neamtu, Mihai Rosu, Ciprian Duta, Andreea Clim, Gabriel Lazar, Bogdan Totolici
Dyslipidemia is a component of metabolic syndrome, having an important role in the carcinogenesis of different tumor types, such as prostate, ovarian, or renal cancer. The number of studies on the predictive potential of the different components of the lipid profile with a predictive potential in breast cancer is quite low. The evaluation of the lipid profile was carried out for the 142 patients who benefited from neoadjuvant therapy (NAC) in order to identify a potential predictive biomarker. The serological sample collection was performed sequentially according to a standardized protocol, pre-NAC, post-NAC and 6 months post-NAC after a 6-h pre-collection fast...
March 31, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612711/pfdn4-as-a-prognostic-marker-was-associated-with-chemotherapy-resistance-through-crebp1-aurka-pathway-in-triple-negative-breast-cancer
#22
JOURNAL ARTICLE
Shih-Ho Wang, Cheng-Hsi Yeh, Chia-Wei Wu, Chia-Yi Hsu, Eing-Mei Tsai, Chao-Ming Hung, Yi-Wen Wang, Tsung-Hua Hsieh
Breast cancer is the most common malignancy and its incidence is increasing. It is currently mainly treated by clinical chemotherapy, but chemoresistance remains poorly understood. Prefolded proteins 4 (PFDN4) are molecular chaperone complexes that bind to newly synthesized polypeptides and allow them to fold correctly to stabilize protein formation. This study aimed to investigate the role of PFDN4 in chemotherapy resistance in breast cancer. Our study found that PFDN4 was highly expressed in breast cancer compared to normal tissues and was statistically significantly associated with stage, nodal status, subclasses (luminal, HER2 positive and triple negative), triple-negative subtype and disease-specific survival by TCGA database analysis...
March 31, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38611103/the-impact-of-adjunct-medical-therapy-on-survival-after-spine-metastasis-a-systematic-review-and-pooled-data-analysis
#23
REVIEW
Lilly Groszman, Jonathan A Hubermann, Paul Kooner, Nawaf Alamiri, Anthony Bozzo, Ahmed Aoude
Targeted therapy has greatly improved the outlook for patients with spinal metastatic cancers. Scoring systems like the Tokuhashi or Tomita scores are commonly used to predict prognosis and inform surgical decisions, but they are outdated and fail to consider recent advancements. We aimed to investigate the current state of the literature and treatment options pertaining to advancements in targeted therapy compared to other forms of medical management for metastatic spinal tumors. This study represents the first comprehensive systematic review that encompasses the most common primary cancers that metastasize to the spine and evaluates the median overall survival (mOS) across five different medical treatment modalities as well as surgical intervention...
April 7, 2024: Cancers
https://read.qxmd.com/read/38611046/fxr-agonism-with-bile-acid-mimetic-reduces-pre-clinical-triple-negative-breast-cancer-burden
#24
JOURNAL ARTICLE
Sydney C Joseph, Samson Eugin Simon, Margaret S Bohm, Minjeong Kim, Madeline E Pye, Boston W Simmons, Dillon G Graves, Stacey M Thomas-Gooch, Ubaid A Tanveer, Jeremiah R Holt, Suriyan Ponnusamy, Laura M Sipe, D Neil Hayes, Katherine L Cook, Ramesh Narayanan, Joseph F Pierre, Liza Makowski
Bariatric surgery is associated with improved outcomes for several cancers, including breast cancer (BC), although the mechanisms mediating this protection are unknown. We hypothesized that elevated bile acid pools detected after bariatric surgery may be factors that contribute to improved BC outcomes. Patients with greater expression of the bile acid receptor FXR displayed improved survival in specific aggressive BC subtypes. FXR is a nuclear hormone receptor activated by primary bile acids. Therefore, we posited that activating FXR using an established FDA-approved agonist would induce anticancer effects...
March 30, 2024: Cancers
https://read.qxmd.com/read/38611040/breast-tumor-tissue-image-classification-using-single-task-meta-learning-with-auxiliary-network
#25
JOURNAL ARTICLE
Jiann-Shu Lee, Wen-Kai Wu
Breast cancer has a high mortality rate among cancers. If the type of breast tumor can be correctly diagnosed at an early stage, the survival rate of the patients will be greatly improved. Considering the actual clinical needs, the classification model of breast pathology images needs to have the ability to make a correct classification, even in facing image data with different characteristics. The existing convolutional neural network (CNN)-based models for the classification of breast tumor pathology images lack the requisite generalization capability to maintain high accuracy when confronted with pathology images of varied characteristics...
March 30, 2024: Cancers
https://read.qxmd.com/read/38610931/metastatic-breast-cancer-prolonging-life-in-routine-oncology-care
#26
JOURNAL ARTICLE
Rudolf Weide, Stefan Feiten, Christina Waßmann, Bernhard Rendenbach, Ute Braun, Oswald Burkhard, Peter Ehscheidt, Marcus Schmidt
Overall survival (OS) of patients with metastatic breast cancer (MBC) has improved within controlled clinical trials. Whether these advances translate into improved OS in routine care is controversial. We therefore analyzed retrospectively unselected female patients from five oncology group practices and one university outpatient clinic, whose initial diagnosis of MBC was between 1995 and 2022. A total of 1610 patients with a median age of 63 years (23-100) were evaluated. In all, 82.9% had hormone-receptor-positive disease, and 23...
March 22, 2024: Cancers
https://read.qxmd.com/read/38610786/traditional-clinicopathological-biomarkers-still-determine-disease-free-and-overall-survival-in-invasive-breast-cancer-patients-a-pilot-study
#27
JOURNAL ARTICLE
Katarzyna Wrzeszcz, Katarzyna Kwiatkowska, Piotr Rhone, Dorota Formanowicz, Stefan Kruszewski, Barbara Ruszkowska-Ciastek
Background: Molecular classification, tumor diameter, Ki67 expression, and brachytherapy administration still act as the most potent potential predictors of breast cancer recurrence and overall survival. Methods: Over the period of 23 months, we included in the study 92 invasive breast cancer (IBrC) patients initially diagnosed at the Clinical Ward of Breast Cancer and Reconstructive Surgery, Oncology Center in Bydgoszcz, Poland. The probability of disease-free survival (DFS) and overall survival (OS) in relation to potential prognostic factors for the patients were determined using a Kaplan-Meier analysis, and univariate and multivariate Cox regression analyses evaluated the predictive factors of IBrC patients...
March 30, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38609794/comparison-of-clinical-breast-exam-to-breast-mri-surveillance-in-patients-following-nipple-sparing-mastectomy
#28
JOURNAL ARTICLE
Christina Weed, Ton Wang, Srivarshini C Mohan, Xuanji Wang, Joshua Tseng, Theodore Hu, Jutla Jaswinder, Marissa K Boyle, Farin Amersi, Armando Giuliano, Alice Chung
BACKGROUND: Nipple sparing mastectomy (NSM) is increasingly being performed for patients with breast cancer. However, optimal postoperative surveillance has not been defined. METHODS: A prospectively maintained database identified patients with in-situ and invasive cancer who underwent NSM between 2007-2021. Clinical data on postoperative breast surveillance and interventions were collected. Patients who had MRI surveillance versus clinical breast exam (CBE) alone were compared with respect to tumor characteristics, recurrence, and survival...
March 20, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38609112/the-effect-of-a-multimodal-approach-on-the-results-of-treatment-in-surgery-integration-of-chemotherapy-surgery-and-radiotherapy
#29
JOURNAL ARTICLE
V Vovk, I Duda, A Vovk
This study investigates the safety and efficacy of a multimodal approach, integrating radiotherapy, chemotherapy, and surgery for the management of cancer patients. This review systematically reviewed English-language literature from digital repositories, namely Web of Science, Scopus, Google Scholar, PubMed, and the Cochrane Library. The search strategy employed a targeted selection of keywords: "chemotherapy," "radiotherapy," "multimodal," and "surgery," encompassing publications published before January 2024...
February 2024: Georgian Medical News
https://read.qxmd.com/read/38608123/the-role-of-transcription-factor-foxa1-c2-m1-o3-p1-q1-in-breast-cancer
#30
JOURNAL ARTICLE
Hui Yuan, Yu Liang, Shaorun Hu, Jinxiang Chen, Jingcan You, Jun Jiang, Mao Luo, Min Zeng
Breast cancer is a common malignancy with the highest mortality rate among women worldwide. Its incidence is on the rise year after year, accounting for more than one-tenth of new cancers worldwide. Increasing evidence suggests that forkhead box (FOX) transcription factors play an important role in the occurrence and development of breast cancer. However, little is known about the relationship between the expression, prognostic value, function, and immune infiltration of FOX transcription factors in tumor microenvironment...
April 12, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38606101/locoregional-recurrence-and-survival-of-breast-conserving-surgery-compared-to-mastectomy-following-neoadjuvant-chemotherapy-in-operable-breast-cancer
#31
JOURNAL ARTICLE
Fa-You Lv, Zongming Mo, Binjie Chen, Zhen Huang, Qinguo Mo, Qixing Tan
BACKGROUND: The risk of locoregional recurrence (LRR) and the long-term prognosis of breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC) are still controversial. This study aimed to evaluate oncological outcomes for patients undergoing BCS after NAC and determine LRR and survival predictors. METHODS: This study was a retrospective cohort study of patients with locally advanced breast cancer (LABC) who received NAC and underwent BCS or mastectomy from June 2011 to November 2020...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38604544/novel-combinatorial-autophagy-inhibition-therapy-for-triple-negative-breast-cancers
#32
JOURNAL ARTICLE
Yomna S Abd El-Aziz, Taymin du Toit-Thompson, Matthew J McKay, Mark P Molloy, Shihani Stoner, Betty McDowell, Elizabeth Moon, Loretta Sioson, Amy Sheen, Angela Chou, Anthony J Gill, Patric J Jansson, Sumit Sahni
BACKGROUND: Triple negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes. It is characterized by lack of estrogen, progesterone and human epidermal growth factor 2 receptors, and thus, have limited therapeutic options. Autophagy has been found to be correlated with poor prognosis and aggressive behaviour in TNBC. This study aimed to target autophagy in TNBC via a novel approach to inhibit TNBC progression. METHODS: Immunoblotting and confocal microscopy were carried out to examine the effect of tumor microenvironmental stressors on autophagy...
April 9, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38604109/resonance-of-fatty-acid-metabolism-and-immune-infiltration-in-anti-pd-1-monotherapy-for-breast-cancer
#33
JOURNAL ARTICLE
Andi Zhao, Jin Yang, Ran Ran, Shidi Zhao, Yuxin Cui, Fang Hu, Yan Zhou
The interaction between tumor fatty acid metabolism and immune microenvironment is a novel topic in oncology research, and the relationship of lipid-derived factors with immune editing in tumor is unclear. The breast cancer samples from the TCGA database were used as the training set, and samples from GSE42568 were employed as the validation set for constructing a model to identify a signature associated with fatty acid metabolism through Lasso Cox regression. And the changes in immune related signatures and risk score before and after anti-PD-1 monotherapy were caught by the differential analysis in GSE225078...
April 10, 2024: Translational Oncology
https://read.qxmd.com/read/38603927/association-of-preoperative-and-postoperative-circulating-tumour-dna-ctdna-with-pik3ca-gene-mutation-with-risk-of-recurrence-in-patients-with-non-metastatic-breast-cancer
#34
JOURNAL ARTICLE
Fara Hassan, Jiang Huai Wang, Donal Peter O'Leary, Mark Corrigan, Henry Paul Redmond
BACKGROUND: Circulating tumour DNA (ctDNA), contains tumour-specific gene mutation in blood circulation and could aid in postoperative risk stratification of non-metastatic breast cancer. In this study, we investigated the feasibility of detecting PIK3CA gene mutations in ctDNA in the preoperative (preop) and postoperative period (postop), and its prognostic significance in patients with breast cancer. METHODS: A cohort of patients with breast cancer undergoing curative surgery with available blood samples preoperatively and postoperatively (Post op) at either Post op time period; week 1-2, week 3-4 or weeks 5-12 were enrolled...
March 5, 2024: Surgical Oncology
https://read.qxmd.com/read/38603658/real-world-evidence-of-ribociclib-plus-aromatase-inhibitors-as-first-line-treatment-in-advanced-breast-cancer-the-brasileeira-study
#35
JOURNAL ARTICLE
Daniele Assad Suzuki, Alessandra Menezes Morelle, Mayana Lopes de Brito, Flavia Rocha Paes, André Mattar, Jorge H Santos Leal, Sérgio D Simon, Ellias Magalhães Abreu Lima, Gustavo Werutsky, Gustavo H Munhoz Piotto, José Bines, Lucas Petri Damiani, Ariane Macedo, Lígia Campos, Anna Maria Buehler
PURPOSE: Cyclin inhibitors plus endocrine therapy represent the reference standard for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer (ABC). Efficacy results on hard end points such as overall survival come from well-designed randomized clinical trials (RCTs). However, a limitation of RCTs is the low external results validity, and their extrapolation to a broader population may not be appropriate. Real-world studies can overcome these limitations, also increasing the reliability of RCTs...
April 2024: JCO global oncology
https://read.qxmd.com/read/38603651/phase-ii-study-of-erdafitinib-in-patients-with-tumors-with-fgfr-amplifications-results-from-the-nci-match-ecog-acrin-trial-eay131-subprotocol-k1
#36
JOURNAL ARTICLE
Jun Gong, Alain C Mita, Zihan Wei, Heather H Cheng, Edith P Mitchell, John J Wright, S Percy Ivy, Victoria Wang, Robert C Gray, Lisa M McShane, Larry V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton, Ajjai S Alva, James V Tricoli, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty
PURPOSE: Despite fibroblast growth factor receptor ( FGFR ) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies. Subprotocol K1 (EAY131-K1) of the National Cancer Institute-MATCH platform trial was designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 amplification. METHODS: EAY131-K1 was an open-label, single-arm, phase II study with central confirmation of presence of FGFR1-4 amplification in tumors...
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38602657/anatomical-assessment-of-local-recurrence-site-in-breast-cancer-patients-after-breast-reconstruction-and-post-mastectomy-radiotherapy-implications-for-radiation-volumes-and-techniques
#37
JOURNAL ARTICLE
Viola Salvestrini, Marianna Valzano, Icro Meattini, Carlotta Becherini, Luca Visani, Giulio Francolini, Ilaria Morelli, Niccolò Bertini, Lorenzo Orzalesi, Marco Bernini, Simonetta Bianchi, Gabriele Simontacchi, Lorenzo Livi, Isacco Desideri
INTRODUCTION: Post-mastectomy radiotherapy (PMRT) improves local control rates and survival in patients with adverse prognostic features. The dose coverage to target volumes is critical to yield maximum benefit to treated patients, increasing local control and reducing risk of toxicity. This study aims to assess patterns of breast cancer relapse in patients treated with mastectomy, breast reconstruction and PMRT. METHODS: Breast cancer patients treated with PMRT between 1992 and 2017 were retrospectively reviewed...
April 11, 2024: La Radiologia Medica
https://read.qxmd.com/read/38601487/efficacy-and-safety-of-first-line-treatment-for-metastatic-triple-negative-breast-cancer-a-network-meta-analysis
#38
REVIEW
Mingqiang Shi, Zhoujuan Li, Guoshuang Shen, Tianzhuo Wang, Jinming Li, Miaozhou Wang, Zhen Liu, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao
BACKGROUND: Metastatic triple-negative breast cancer (mTNBC) is an aggressive histological subtype with poor prognosis. Several first-line treatments are currently available for mTNBC. This study conducted a network meta-analysis to compare these first-line regimens and to determine the regimen with the best efficacy. METHODS: A systematic search of PubMed, EMBASE, the Cochrane Central Register of Controlled Bases, and minutes of major conferences was performed...
April 2024: Cancer Pathog Ther
https://read.qxmd.com/read/38601297/mucoepidermoid-carcinoma-a-rare-salivary-gland-type-tumor-of-the-breast-are-we-dealing-with-primary-or-secondary-a-case-report-and-literature-review
#39
Janice S Zhang, Fardeen Bhimani, Sonali Lanjewar, Sheldon Feldman, Maureen McEvoy, Jessica Pastoriza, Anjuli Gupta
BACKGROUND: Salivary gland-like tumors are extremely unusual in the breast, and their histology is very similar to primary salivary gland neoplasms. Mucoepidermoid carcinoma (MEC), a common salivary gland tumor, displays an infrequent occurrence in the breast, accounting for a mere 0.2-0.3% incidence. Given its rarity, it is critical to accurately distinguish it from metastatic cases before diagnosing it as a primary breast MEC for appropriate treatment. Currently, there is no consensus on the treatment of MEC, and there is a paucity of literature highlighting the ideal treatment modality, especially for estrogen receptor (ER)-positive cancers...
March 27, 2024: Gland Surgery
https://read.qxmd.com/read/38600429/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer-patients-treated-at-institut-curie-hospitals-efficacy-safety-and-impact-of-brain-metastases
#40
JOURNAL ARTICLE
Alexandre De Moura, Delphine Loirat, Sarah Vaillant, Sinen Korbi, Nicolas Kiavue, Diana Bello Roufai, Laurence Escalup, Romain Desmaris, Pauline Vaflard, Paul Cottu, Jean-Yves Pierga, François-Clément Bidard, Luc Cabel, Alexandre Acramel
BACKGROUND: Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results. METHODS: We set up an ambispective bicentric cohort study to assess the real-world effectiveness and safety of SG in patients with mTNBC treated at Institut Curie Hospitals, with a focus on patients with brain metastases. RESULTS: This study included 99 patients treated through the French Early Access Program to SG from May 2021 to January 2023...
April 10, 2024: Breast Cancer: the Journal of the Japanese Breast Cancer Society
keyword
keyword
107111
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.